cas 123344-02-5|| where to buy 2,4-Difluoro-5-nitroaniline

Nom du produit:2,4-Difluoro-5-nitroaniline

IUPAC Name:2,4-difluoro-5-nitroaniline

Unité d'emballage	Stock disponible	Prix($)
CM118614-5g	in stock	ħƴ
CM118614-10g	in stock	ţǎħ
CM118614-25g	in stock	Žţǎ
CM118614-100g	1-2 Weeks	ħŁǎ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 123344-02-5 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:123344-02-5; Formule moléculaire:C6H4F2N2O2; Point de fusion:-; Code SMILES:NC1=CC([N+]([O-])=O)=C(F)C=C1F; Densité:

: Numéro de catalogue:CM118614; Poids moléculaire:174.11; Point d'ébullition:; N° Mdl:MFCD04038395; Stockage:Keep in dark place, store at room temperature.

: Benzenes; Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

: Osimertinib; TAGRISSO (osimertinib) demonstrated overwhelming efficacy benefit for patients with unresectable, Stage III EGFR-mutated lung cancer in LAURA Phase III trial.
TAGRISSO (osimertinib) is a third-generation, irreversible EGFR-TKI with proven clinical activity in NSCLC, including against central nervous system metastases. It is the first and only EGFR TKI recommended by NCCN Guidelines as an adjuvant treatment option for completely resected stage IB-IIIA, stage IIIB (T3, N2) EGFRm (exon 19 deletion, exon 21 L858R mutation) NSCLC.